Gore ASSURED Clinical Study results through 36 months demonstrate 100 percent closure success * with the GORE ® CARDIOFORM ASD Occluder, and consistent safety outcomes † across a broad range of ASD ...

FLAGSTAFF, Ariz.- W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration's (FDA's) premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder for the percutaneous closure of ...

After a decade of clinical use* and more than 50,000 devices sold globally, the GORE® CARDIOFORM Septal Occluder continues a trusted legacy of safely advancing care. FLAGSTAFF, Ariz., Jan. 20, 2022 ...

W.L. Gore is bringing its Cardioform ASD Occluder to Europe. The Flagstaff, AZ-based company announced Wednesday it received CE mark for the device, which can close atrial defects (ASDs). The device ...

FLAGSTAFF, Ariz. Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes, W. L. Gore & Associates, Inc.

The FDA has given its final nod to W.L. Gore & Associates Inc. to market the Cardioform ASD occluder, aimed at correcting a congenital anomaly that causes a hole in the wall between the two upper ...

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) announces positive results from its REDUCE Study assessing closure of patent foramen ovale (PFO) for the reduction of recurrent ...

FLAGSTAFF, Ariz., April 3, 2018 /PRNewswire/ -- Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes, W.

After a decade of clinical use* and more than 50,000 devices sold globally, the GORE® CARDIOFORM Septal Occluder continues a trusted legacy of safely advancing care. Now, after 10 years of clinical ...

After a decade of clinical use* and more than 50,000 devices sold globally, the GORE CARDIOFORM Septal Occluder continues a trusted legacy of safely advancing care. FLAGSTAFF, Ariz., Jan. 20, 2022 ...